- Pharmaceutical Technology's In the Lab eNewsletter 06-02-2021
- Volume 16
- Issue 6
Challenges When Outsourcing Viral Safety Services
Assessing biosafety using NGS-based tests requires a continuum of skills in molecular biology, biocomputing, virology, and quality systems.
Nowadays, many biopharmaceutical operations are outsourced, from R&D to regulatory-driven testing services. These outsourcing activities require a network of partners working hand-in-hand, as a global ecosystem, to bring new and critical medicines to patients in need. Biopharmaceutical companies are increasingly outsourcing to contract research organizations (CROs) and contract manufacturing organizations (CMOs) to not only keep pace with market demands, but also enable rapid expansion of development and manufacturing capabilities, source partners for innovative early stage R&D programs, and achieve greater cost efficiency in resource and expertise utilization.
About the authors
Laurent Lafferrère, PhD, is chief operating officer, and Audrey Brussel*, PhD, audrey.brussel@pathoquest.com, is Viral Safety leader; both are at PathoQuest.
*To whom all correspondence should be addressed.
Articles in this issue
over 4 years ago
MedPharm to Expand its UK Analytical Service Labsover 4 years ago
PPD Opens Multipurpose Clinical Research Laboratory in Chinaover 4 years ago
Sphere Fluidics Enhances Capabilities of its Cyto-Mine SystemNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
